{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:43:02Z","timestamp":1794109382057,"version":"4.8.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness and safety of satralizumab over 2.5\u2009years using medical data charts of satralizumab-treated Japanese patients with aquaporin-4 immunoglobulin-G seropositive neuromyelitis optica spectrum disorder (AQP4[+] NMOSD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Major findings:<\/jats:title>\n                    <jats:p>Overall, 124 patients were evaluated (mean\u2009\u00b1\u2009standard deviation: age, 51.1\u2009\u00b1\u200914.0\u2009years; disease duration, 7.0 [6.0] years). At baseline, 72.6%, 16.9%, and 35.5% of patients received oral glucocorticoids (GCs), azathioprine (AZA), and tacrolimus (TAC), respectively. The annualized relapse rate (ARR [95% confidence interval]) decreased from 0.45 (0.34\u20130.58) within 52\u2009weeks before satralizumab initiation to 0.03 (0.02\u20130.07) after 130\u2009weeks of satralizumab initiation; relapse-free rate was 91.8% at 130\u2009weeks. Nine patients had nine relapses; seven were re-administered satralizumab after relapse. At 130\u2009weeks, 48.8% of relapse-free patients were not receiving oral GCs (89.3% received \u2a7d5\u2009mg\/day); mean oral GC dose reduced from 10.3 to 2.5\u2009mg\/day. In patients receiving AZA and TAC at baseline, 80.0% and 47.1% were no longer receiving AZA and TAC at 130\u2009weeks, respectively. Serious drug reactions occurred in 9.7% of patients (serious infections, 6.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The real-world relapse-free rate at 2.5\u2009years was 91.8% (ARR\u2009=\u20090.03) in satralizumab-treated patients with AQP4[+] NMOSD, supporting the relapse-preventive effect of satralizumab without new safety concerns.<\/jats:p>\n                    <jats:p>Registration number: UMIN000050027<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585261418536","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:39:31Z","timestamp":1771922371000},"page":"302-314","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study)"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4156","authenticated-orcid":false,"given":"Kazuo","family":"Fujihara","sequence":"first","affiliation":[{"name":"Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Fukushima, Japan; Multiple Sclerosis &amp; Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9525-4254","authenticated-orcid":false,"given":"Noriko","family":"Isobe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0349-9842","authenticated-orcid":false,"given":"Katsuichi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-920X","authenticated-orcid":false,"given":"Masaaki","family":"Niino","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5858-0998","authenticated-orcid":false,"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics, Graduate School of Medicine and Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-8337","authenticated-orcid":false,"given":"Masami","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Kyoto MS Center, Kyoto Min-Iren Chuo Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-4750","authenticated-orcid":false,"given":"Masayuki","family":"Tahara","sequence":"additional","affiliation":[{"name":"Clinical Research Center and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzumura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kaikoukai Josai Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9516-6753","authenticated-orcid":false,"given":"Kenzo","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8903-8600","authenticated-orcid":false,"given":"Nobuaki","family":"Yoshikura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Shiomi","sequence":"additional","affiliation":[{"name":"Division of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5188-063X","authenticated-orcid":false,"given":"Hirofumi","family":"Ochi","sequence":"additional","affiliation":[{"name":"Department of Intractable Disease and Aging Science, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6902-8309","authenticated-orcid":false,"given":"Eiichiro","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokai University School of Medicine, Isehara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Deguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tomizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-1609","authenticated-orcid":false,"given":"Katsuhisa","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5670-1698","authenticated-orcid":false,"given":"Tadashi","family":"Nagatsuka","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Adachi","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-8948","authenticated-orcid":false,"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02249-1"},{"key":"e_1_3_3_5_2","unstructured":"Japanese Society of Neurology. https:\/\/www.neurology-jp.org\/files\/images\/20230317_01_01.pdf (2023 accessed 20 May 2025)."},{"key":"e_1_3_3_6_2","unstructured":"Japanese prescribing information. Package insert information of satralizumab https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/450045_6399428G1024_1_05 (2025 accessed 30 July 2025)."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105502"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00640-7"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106384"},{"key":"e_1_3_3_12_2","unstructured":"Ethical guidelines for medical and biological research involving human subjects. Ministry of Health Labour and Welfare https:\/\/www.mext.go.jp\/content\/20250325-mxt_life-000035486-01.pdf (2021 accessed 20 May 2025)."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2307\/2530286"},{"key":"e_1_3_3_14_2","article-title":"Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar","volume":"10","author":"Kleiter I","year":"2022","unstructured":"Kleiter I, Traboulsee A, Palace J, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm 2022; 10: e200071.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231181177"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105829"},{"key":"e_1_3_3_17_2","article-title":"Long-term prednisone in doses of less than 5 mg\/day for treatment of rheumatoid arthritis: Personal experience over 25 years","volume":"29","author":"Pincus T","year":"2011","unstructured":"Pincus T, Castrej\u00f3n I, Sokka T. Long-term prednisone in doses of less than 5 mg\/day for treatment of rheumatoid arthritis: Personal experience over 25 years. Clin Exp Rheumatol 2011; 29(5, Suppl. 68): S130\u2013S138.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu135"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1166490"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261418536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585261418536","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261418536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:47:16Z","timestamp":1779356836000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585261418536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/13524585261418536"],"URL":"https:\/\/doi.org\/10.1177\/13524585261418536","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}